Commenting on the decision, Stephen Whitehead Chief Executive of the ABPI, said:
“The ABPI is disappointed that the SSCIF has been suspended. The SCCIF fund was part of the much lauded Innovation Health and Wealth (IHW) programme, and it had the potential to benefit patients through facilitating and accelerating the adoption of innovative treatments and services. We hope that this decision will not stifle innovation and that patients will not miss out on accessing innovative new medicines as a result. It is important that there are no further cuts or suspensions to the IHW programme as this will almost certainly impact on patients.
"However, we welcome the on-going commitment given by NHS England Specialised Services to continue to lead and facilitate the uptake and spread of innovation, and the confirmation that innovation will be a key part of the developing Five Year Specialised Commissioning Strategy."
ABPI Press Office
Tel: +44 (0) 20 7747 1441 or +44 20 7747 1410
Mobile: +44 (0) 7808 641811 or +44 7850 312064
Notes to editor
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.